Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of “Moderate Buy” from Analysts

Coya Therapeutics, Inc. (NASDAQ:COYA) has earned a consensus recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $15.3333.

A number of equities research analysts have weighed in on the company. BTIG Research restated a “buy” rating and set a $16.00 price objective on shares of Coya Therapeutics in a research note on Tuesday, September 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Friday, July 17th. HC Wainwright restated a “buy” rating on shares of Coya Therapeutics in a research note on Monday, August 24th. Roth Capital reaffirmed a “buy” rating and set a $12.00 price target on shares of Coya Therapeutics in a research report on Monday, August 24th. Finally, Chardan Capital reiterated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Wednesday, August 12th.

Coya Therapeutics Trading Up 1.2%

NASDAQ COYA opened at $4.95 on Tuesday. The stock has a market cap of $116.13 million, a P/E ratio of -4.63 and a beta of 0.61. The company’s fifty day simple moving average is $4.61 and its 200-day simple moving average is $4.66. Coya Therapeutics has a 52 week low of $3.71 and a 52 week high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.07. The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.13 million. Coya Therapeutics had a negative net margin of 270.22% and a negative return on equity of 52.05%. On average, research analysts expect that Coya Therapeutics will post -1.34 EPS for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

Large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its stake in Coya Therapeutics by 55.4% during the first quarter. Renaissance Technologies LLC now owns 103,964 shares of the company’s stock valued at $410,000 after purchasing an additional 37,064 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Coya Therapeutics by 205.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 95,919 shares of the company’s stock worth $377,000 after buying an additional 64,490 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in shares of Coya Therapeutics in the 1st quarter worth about $161,000. Long Corridor Asset Management Ltd acquired a new position in shares of Coya Therapeutics in the 4th quarter valued at about $225,000. Finally, Cetera Investment Advisers boosted its holdings in shares of Coya Therapeutics by 36.4% in the 1st quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock valued at $118,000 after buying an additional 8,000 shares during the period. 39.75% of the stock is currently owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies designed to enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune responses and may play a role in limiting inflammation associated with neurodegenerative and autoimmune diseases.

The company’s pipeline includes investigational Treg-based therapies, including COYA 301, an autologous Treg therapy being evaluated for potential use in conditions such as amyotrophic lateral sclerosis (ALS).